Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $58.23 billion. The enterprise value is $43.40 billion.
| Market Cap | 58.23B |
| Enterprise Value | 43.40B |
Important Dates
The last earnings date was Friday, August 1, 2025, before market open.
| Earnings Date | Aug 1, 2025 |
| Ex-Dividend Date | Aug 18, 2025 |
Share Statistics
REGN has 103.69 million shares outstanding. The number of shares has decreased by -1.75% in one year.
| Current Share Class | 101.87M |
| Shares Outstanding | 103.69M |
| Shares Change (YoY) | -1.75% |
| Shares Change (QoQ) | -2.34% |
| Owned by Insiders (%) | 5.42% |
| Owned by Institutions (%) | 86.63% |
| Float | 97.91M |
Valuation Ratios
The trailing PE ratio is 14.15 and the forward PE ratio is 13.96. REGN's PEG ratio is 1.74.
| PE Ratio | 14.15 |
| Forward PE | 13.96 |
| PS Ratio | 4.22 |
| Forward PS | 3.98 |
| PB Ratio | 1.95 |
| P/TBV Ratio | 2.04 |
| P/FCF Ratio | 15.11 |
| P/OCF Ratio | 12.27 |
| PEG Ratio | 1.74 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.72, with an EV/FCF ratio of 11.26.
| EV / Earnings | 9.73 |
| EV / Sales | 3.05 |
| EV / EBITDA | 9.72 |
| EV / EBIT | 10.97 |
| EV / FCF | 11.26 |
Financial Position
The company has a current ratio of 4.60, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.60 |
| Quick Ratio | 3.57 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.60 |
| Debt / FCF | 0.70 |
| Interest Coverage | 108.11 |
Financial Efficiency
Return on equity (ROE) is 15.34% and return on invested capital (ROIC) is 7.78%.
| Return on Equity (ROE) | 15.34% |
| Return on Assets (ROA) | 6.66% |
| Return on Invested Capital (ROIC) | 7.78% |
| Return on Capital Employed (ROCE) | 11.45% |
| Revenue Per Employee | $940,964 |
| Profits Per Employee | $295,154 |
| Employee Count | 15,106 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 2.46 |
Taxes
In the past 12 months, REGN has paid $416.20 million in taxes.
| Income Tax | 416.20M |
| Effective Tax Rate | 8.54% |
Stock Price Statistics
The stock price has decreased by -49.91% in the last 52 weeks. The beta is 0.33, so REGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -49.91% |
| 50-Day Moving Average | 539.14 |
| 200-Day Moving Average | 648.81 |
| Relative Strength Index (RSI) | 53.24 |
| Average Volume (20 Days) | 986,481 |
Short Selling Information
The latest short interest is 2.29 million, so 2.21% of the outstanding shares have been sold short.
| Short Interest | 2.29M |
| Short Previous Month | 2.07M |
| Short % of Shares Out | 2.21% |
| Short % of Float | 2.34% |
| Short Ratio (days to cover) | 2.55 |
Income Statement
In the last 12 months, REGN had revenue of $14.21 billion and earned $4.46 billion in profits. Earnings per share was $39.67.
| Revenue | 14.21B |
| Gross Profit | 6.73B |
| Operating Income | 3.96B |
| Pretax Income | 4.78B |
| Net Income | 4.46B |
| EBITDA | 4.47B |
| EBIT | 3.96B |
| Earnings Per Share (EPS) | $39.67 |
Balance Sheet
The company has $7.47 billion in cash and $2.71 billion in debt, giving a net cash position of $14.82 billion or $142.96 per share.
| Cash & Cash Equivalents | 7.47B |
| Total Debt | 2.71B |
| Net Cash | 14.82B |
| Net Cash Per Share | $142.96 |
| Equity (Book Value) | 29.94B |
| Book Value Per Share | 287.55 |
| Working Capital | 13.19B |
Cash Flow
In the last 12 months, operating cash flow was $4.74 billion and capital expenditures -$889.80 million, giving a free cash flow of $3.85 billion.
| Operating Cash Flow | 4.74B |
| Capital Expenditures | -889.80M |
| Free Cash Flow | 3.85B |
| FCF Per Share | $37.17 |
Margins
Gross margin is 47.35%, with operating and profit margins of 27.84% and 31.37%.
| Gross Margin | 47.35% |
| Operating Margin | 27.84% |
| Pretax Margin | 34.30% |
| Profit Margin | 31.37% |
| EBITDA Margin | 31.42% |
| EBIT Margin | 27.84% |
| FCF Margin | 27.11% |
Dividends & Yields
This stock pays an annual dividend of $3.52, which amounts to a dividend yield of 0.63%.
| Dividend Per Share | $3.52 |
| Dividend Yield | 0.63% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 6.65% |
| Buyback Yield | 1.75% |
| Shareholder Yield | 2.37% |
| Earnings Yield | 7.66% |
| FCF Yield | 6.62% |
Analyst Forecast
The average price target for REGN is $808.43, which is 43.96% higher than the current price. The consensus rating is "Buy".
| Price Target | $808.43 |
| Price Target Difference | 43.96% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 4.78% |
| EPS Growth Forecast (5Y) | 9.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 8.61 and a Piotroski F-Score of 4.
| Altman Z-Score | 8.61 |
| Piotroski F-Score | 4 |